A recent article discusses Eli Lilly and Company (NYSE:LLY) in the context of the “10 Best Medical Stocks to Buy According to Billionaires.” Mizuho Securities’ Jared Holz addressed the healthcare sector’s perceived resilience amid market volatility, noting challenges such as patent cliffs and pricing pressures that undermine investor confidence. Eli Lilly, however, is highlighted for its strong financial performance and innovative drug pipeline, including a promising collaboration in cancer treatment.